DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
about
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesRegulatory T cell: a protection for tumour cellsDetailed kinetics of the direct allo-response in human liver transplant recipients: new insights from an optimized assayLimited transplantation of antigen-expressing hematopoietic stem cells induces long-lasting cytotoxic T cell responsesSemiallogenic fusions of MSI(+) tumor cells and activated B cells induce MSI-specific T cell responsesEnhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection.Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaLarge-scale in vitro expansion of polyclonal human switched-memory B lymphocytes.Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapyThe role of B cells and humoral immunity in Mycobacterium tuberculosis infectionImpaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cellsProfessional antigen presenting cells in human herpesvirus 8 infection.Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.How B cells shape the immune response against Mycobacterium tuberculosis.Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy.Toll-like receptors and B cells: functions and mechanisms.Generation of human CD40-activated B cells.Murine model of CD40-activation of B cells.Antigen-specific immunotherapies in rheumatic diseases.Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses.Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells.Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell responseDissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures.CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides.Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses
P2860
Q26852437-88D3B84A-1E54-437A-8786-E1F1A41D2A3DQ26991447-11BBDD42-1B4E-4457-B6C6-E0167C006B84Q33785850-2D298E4E-240A-4F1C-87C3-67E35BD56C3AQ33838390-782146D7-6332-48EE-B8B8-E37B555CCFCDQ34028964-1E961F18-A8D5-4973-BE5E-81E21CD207C1Q34105724-AF8D763A-4AF0-4568-98AC-A32138A64C11Q34198563-4106F7B1-F77F-4DB4-859E-C43DBEA6E476Q34532604-872294D4-042A-41F7-871C-9709F917E4FCQ34594769-B7CE71A4-5599-45AA-9CE9-8D419F2D7B4BQ35039807-A5227F16-C187-4390-AB70-7B750DE7297AQ36539717-193FE55B-4DDF-4954-A0FF-AA710D86B427Q36546999-A8510A75-A199-480A-8D7E-5F89FAC5B2A6Q36915898-40053692-CA3E-4D7C-8C31-EAE1A788B70EQ37069120-B164BFF6-164A-4B39-9100-4EAD9A07EE3FQ37383963-97AAC2A1-9D1E-48F4-85B1-CB9FB2F301D6Q37440696-A969E446-5A9B-44FD-AB73-B8E98AD65760Q37564683-31B1A72B-1FCE-4B4E-91B5-8583B125521CQ38213432-1F04A1D3-8966-48F4-A013-06A4479EC820Q38272355-61AA7E70-68EF-4345-98E8-FC1CA85D4929Q38332142-46B02ADA-CCFB-4EA8-88DB-A05B565AC879Q39431371-223736F0-3A36-4798-9D9D-D8FB8EACAFD7Q39763286-B3D5BB01-E008-4631-B51B-533CF39BE94FQ40051360-3B41601F-7077-4277-A36A-857BB85203A8Q40329387-8794386C-417C-4BD2-B040-2BECCB3F60D5Q41773067-6D535C48-80BB-4459-BA47-846DC7BE6A60Q41909731-5356291C-472F-4B52-8512-421541FAB45CQ42255825-01E5FC5F-92B1-4DDC-99F7-FBD812302860Q48371221-55F30856-5F38-4065-A8BB-2751C325C241Q56967539-B8A074FB-C25C-4263-BC48-0E5DBFD6C12B
P2860
DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
DCs and CD40-activated B cells ...... cellular cancer immunotherapy.
@ast
DCs and CD40-activated B cells ...... cellular cancer immunotherapy.
@en
type
label
DCs and CD40-activated B cells ...... cellular cancer immunotherapy.
@ast
DCs and CD40-activated B cells ...... cellular cancer immunotherapy.
@en
prefLabel
DCs and CD40-activated B cells ...... cellular cancer immunotherapy.
@ast
DCs and CD40-activated B cells ...... cellular cancer immunotherapy.
@en
P356
P1433
P1476
DCs and CD40-activated B cells ...... cellular cancer immunotherapy.
@en
P2093
Stephan Grabbe
P304
P356
10.1016/J.IT.2004.09.016
P577
2004-12-01T00:00:00Z